3 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 3 |
Follow Recurrent Melanoma: new trials by email Literature Review of Recurrent Melanoma trials Research Report on Recurrent Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis - Cervical Carcinoma, Esophageal Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2017-11-03 | 2018-10-03 | |
| Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2015-01-01 | 2020-07-27 | |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma sorafenib tosylate, temsirolimus - Melanoma, Recurrent Melanoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2006-04-01 | 2015-04-15 |
Melanoma (3) · Esophageal Neoplasms (1) · Recurrence (1) · Uterine Cervical Neoplasms (1) · Vaginal Neoplasms (1) · Vulvar Neoplasms (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Neuroendocrine Tumors (3) · Nevi and Melanomas (3) · Skin Diseases (3) · Skin Neoplasms (3) · Skin and Connective Tissue Diseases (3) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Esophageal Diseases (1)
CTLA-4 Antigen (1) · Ipilimumab (1) · Nivolumab (1) · Observation (1) · Radiation (1) · Radiotherapy (1) · Sirolimus (1) · Sorafenib (1) · Watchful Waiting (1) · binimetinib (1) · encorafenib (1) · temsirolimus (1)
National Cancer Institute (NCI) (2) · Jonsson Comprehensive Cancer Center (1)
United States (2)
Alexander Shoushtari (1) · Antoni Ribas (1) · Kevin Kim (1)
N01CM62202 (1), P01CA168585 (1), U10CA180821 (1)